Cantor Fitzgerald initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $6 price target CytomX may have a real contender on its hands with CX-051, a masked epithelial cell adhesion molecule antibody-drug conjugate, and one it can build a franchise around, the analyst tells investors in a research note. Cantor likes the setup, saying that if CX-2051 delivers, CytomX owns a first-in-class space with blockbuster potential in colorectal cancer, and optionality well beyond that.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
- CytomX Therapeutics assumed with an Overweight at Barclays
- CytomX Therapeutics initiated with an Overweight at Barclays
- Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event
- CytomX trial ongoing despite grade five event, says Oppenheimer